{"filing":{"accession_number":"0001665988-26-000029","cik":"0001665988","ticker":"BVS","company_name":"Bioventus Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"bvs-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1665988/000166598826000029/bvs-20260521.htm"},"events":[{"id":9590,"run_id":8412,"accession_number":"0001665988-26-000029","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"The FDA reclassified Bioventus's Exogen bone growth stimulator from Class III to Class II, triggering CMS updates to Medicare reimbursement rates effective May 18, 2026. While the company states it does not presently expect a material impact on 2026 results and is reiterating guidance, the disclosure acknowledges potential long-term impacts and notes that \"further changes by CMS...could require the Company to revise its financial outlook.\" This regulatory change affecting a core product's reimbursement is material to investors, though it does not fit neatly into the more specific event categories (not a restatement, impairment, or covenant breach, but a significant regulatory development with acknowledged future financial uncertainty).","company_name":"Bioventus Inc.","ticker":"BVS","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1254,"accession_number":"0001665988-26-000029","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The FDA reclassified Bioventus's Exogen bone growth stimulator from Class III to Class II, triggering CMS updates to Medicare reimbursement rates effective May 18, 2026. While the company states it does not presently expect a material impact on 2026 results and is reiterating guidance, the disclosure acknowledges potential long-term impacts and notes that \"further changes by CMS...could require the Company to revise its financial outlook.\" This regulatory change affecting a core product's reimbursement is material to investors, though it does not fit neatly into the more specific event categories (not a restatement, impairment, or covenant breach, but a significant regulatory development with acknowledged future financial uncertainty).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:21:26.589488+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1254,"accession_number":"0001665988-26-000029","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The FDA reclassified Bioventus's Exogen bone growth stimulator from Class III to Class II, triggering CMS updates to Medicare reimbursement rates effective May 18, 2026. While the company states it does not presently expect a material impact on 2026 results and is reiterating guidance, the disclosure acknowledges potential long-term impacts and notes that \"further changes by CMS...could require the Company to revise its financial outlook.\" This regulatory change affecting a core product's reimbursement is material to investors, though it does not fit neatly into the more specific event categories (not a restatement, impairment, or covenant breach, but a significant regulatory development with acknowledged future financial uncertainty).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T03:21:26.589488+00:00","company_name":"Bioventus Inc.","ticker":"BVS","filing_date":"2026-05-21"}]}